Evaxion (EVAX) news
Recent news
Evaxion Q2 basic EPS USD -0.01
Evaxion A/S (NASDAQ: EVAX) reported a basic and diluted earnings per share (EPS) of -$0.12 for the second quarter of 2024, reflecting continued net loss for the clinical-stage biotechnology firm. This performance aligns with the company’s ongoing investment in its AI-Immunology™ platform and…
AInvest Wire · Aug 20, 2026Evaxion Q2 pretax profit USD -3.933 million
AInvest Wire · Aug 20, 2026Evaxion Q2 operating income USD -3.846 million
AInvest Wire · Aug 20, 2026Evaxion announces business update and second quarter 2026 financial results
AInvest Wire · Aug 20, 2026Evaxion Q2 net income USD -3.729 million
Evaxion Biotech A/S (EVAX) reported a net income of USD -3.729 million for the second quarter of 2025, reflecting continued financial challenges for the biotechnology firm. The company’s earnings per share (EPS) for the quarter were not disclosed in the available data, but historical trends…
AInvest Wire · Aug 20, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.